Ma Victoria Escarda, APRN
Psychiatric/Mental Health · Las Vegas, NVNPI 1962883553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 493 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- plus $3K from 14 others
What the payments were for
- Food & beverage$11,88998%
- Education$2572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $1,846 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,777 |
| Johnson & Johnson | 53 | $1,775 |
| Neurocrine Biosciences, Inc. | 45 | $1,387 |
| Otsuka America Pharmaceutical, Inc. | 51 | $1,298 |
| Alkermes, Inc. | 38 | $1,008 |
| Teva Pharmaceuticals USA, Inc. | 15 | $558 |
| Axsome Therapeutics, Inc. | 21 | $396 |
| Almatica Pharma LLC | 17 | $347 |
| Avanir Pharmaceuticals, Inc. | 16 | $340 |
| Lundbeck LLC | 19 | $321 |
| E.r. Squibb & Sons, L.L.C. | 14 | $305 |
| Supernus Pharmaceuticals, Inc. | 13 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $216 |
| Indivior Inc. | 5 | $152 |
| Vanda Pharmaceuticals Inc. | 4 | $59 |
| Tempus AI, Inc | 2 | $56 |
| Neuronetics, Inc. | 1 | $30 |
| Merck | 2 | $30 |
| Sage Therapeutics, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$912
- LYBALVI$845
- CAPLYTA$615
- VRAYLAR$600
- SPRAVATO$499
- ABILIFY MAINTENA$244
- REXULTI$235
- INVEGA SUSTENNA$125
- AUSTEDO$125
- NUEDEXTA$121
- ABILIFY ASIMTUFII$120
How this compares
$12,146 in reported general payments places this provider in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $117,964 |
| VraylarCariprazine Hcl | 42 | $74,426 |
| Abilify MaintenaAripiprazole | 18 | $50,158 |
| Invega SustennaPaliperidone Palmitate | 17 | $42,556 |
| Quetiapine Fumarate | 79 | $2,305 |
| Alprazolam | 246 | $1,413 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,037 |
| Divalproex Sodium | 31 | $738 |
| Trazodone Hcl | 108 | $731 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 87 | $706 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $662 |
| Buspirone Hcl | 35 | $617 |
| Sertraline Hcl | 106 | $567 |
| Risperidone | 41 | $561 |
| Fluvoxamine Maleate | 12 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,387 | $117,96414 claims |
| AbbVieVraylar | $1,846 | $74,42642 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,298 | $50,15818 claims |
| Johnson & JohnsonInvega Sustenna | $1,775 | $42,55617 claims |
| Almatica Pharma LLCSertraline Hcl | $347 | $567106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Las Vegas
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
- Sydney EganLas Vegas$14K
- Carminia SalvacionLas Vegas$12K
- Valentina AkohLas Vegas$12K
- Angela WilsonLas Vegas$11K
- Michael MathisenLas Vegas$10K
- Edina BorosLas Vegas$9K
- Salem FitsumLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.